NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis $41.72 -0.06 (-0.14%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$41.74 +0.02 (+0.06%) As of 06/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About XOMA Royalty Stock (NASDAQ:XOMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$41.54▼$41.9650-Day Range$34.58▼$42.4052-Week Range$22.29▼$42.81Volume80,470 shsAverage Volume100,632 shsMarket Capitalization$523.21 millionP/E Ratio26.57Dividend YieldN/APrice Target$53.75Consensus RatingHold Company Overview XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders. The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways. Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.AI Generated. May Contain Errors. Read More XOMA Royalty Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreXOMA MarketRank™: XOMA Royalty scored higher than 51% of companies evaluated by MarketBeat, and ranked 518th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingXOMA Royalty has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.Upside PotentialXOMA Royalty has a consensus price target of $53.75, representing about 28.8% upside from its current price of $41.72.Amount of Analyst CoverageXOMA Royalty has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about XOMA Royalty's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for XOMA Royalty are expected to decrease in the coming year, from $0.90 to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA Royalty is 26.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA Royalty is 26.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.78.Price to Book Value per Share RatioXOMA Royalty has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA Royalty's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.46% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 8.25.Change versus previous monthShort interest in XOMA Royalty has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA Royalty does not currently pay a dividend.Dividend GrowthXOMA Royalty does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentXOMA Royalty has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for XOMA Royalty this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XOMA Royalty insiders have not sold or bought any company stock.Percentage Held by Insiders8.90% of the stock of XOMA Royalty is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA Royalty's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMA Stock News HeadlinesXOMA Highlights Royalty Aggregation Strategy in Updated PresentationJune 16 at 7:34 PM | theglobeandmail.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 13, 2026 | seekingalpha.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)XOMA Details Merger Timeline and Preferred Share RedemptionJune 12, 2026 | tipranks.comXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateJune 12, 2026 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average - Here's What HappenedJune 12, 2026 | americanbankingnews.comXOMA Royalty Sets July Vote on $39-per-Share Ligand Takeover and ReorganizationJune 10, 2026 | tipranks.comXOMA (XOMA) Q4 2025 Earnings Call TranscriptJune 2, 2026 | finance.yahoo.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA Royalty's stock was trading at $26.59 on January 1st, 2026. Since then, XOMA stock has increased by 56.9% and is now trading at $41.72. How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) issued its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by $0.02. The biotechnology company earned $12.32 million during the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a trailing twelve-month return on equity of 12.56% and a net margin of 53.46%. Who are XOMA Royalty's major shareholders? Top institutional shareholders of XOMA Royalty include Dimensional Fund Advisors LP (1.12%), Bank of New York Mellon Corp (0.63%), Bank of America Corp DE (0.09%) and Royal Bank of Canada (0.01%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Thomas M Burns, Joseph M Limber and Bradley Sitko. View institutional ownership trends. How do I buy shares of XOMA Royalty? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/12/2026Today6/17/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 XOMA's financial health is in the Green zone, according to TradeSmith. XOMA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$53.75 High Price Target$76.00 Low Price Target$39.00 Potential Upside/Downside+28.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio26.57 Forward P/E Ratio46.36 P/E GrowthN/ANet Income$31.71 million Net Margins53.46% Pretax Margin69.85% Return on Equity12.56% Return on Assets4.11% Debt Debt-to-Equity Ratio0.96 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$7.65 million Price / Sales68.37 Cash Flow$0.57 per share Price / Cash Flow73.28 Book Value$6.77 per share Price / Book6.16Miscellaneous Outstanding Shares12,541,000Free Float11,425,000Market Cap$523.21 million OptionableOptionable Beta0.88 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:XOMA) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersBuy now or wait?SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
